Chrysalis BioTherapeutics, Inc. is a privately held biopharmaceutical development company working to save lives and improve life’s quality. The company is developing drugs that mimic the body’s natural regenerative signals to activate and protect endogenous endothelial progenitor cells and stem cells located within tissues to repair and regenerate tissues damaged by injury, disease, and radiation exposure.
The company is focused on developing drug products to mitigate effects of two types of radiation exposure.
Radiation Therapy: Radiation Therapy damages normal tissues causing long-term or permanent damage and limiting how much radiation can be used by oncologist to eradicate tumors. Treatment with the company’s lead product Chrysalin® protects normal tissues from damaging effects of radiation therapy without affecting radiation killing of tumor cells.
Nuclear Radiation: There is increasing risk of a nuclear accident or intentional detonation somewhere in the world with no medical solution to save lives and prevent long-term suffering. Injection of Chrysalin® 24 hours after nuclear exposure increases survival and accelerates wound healing in preclinical studies.
The company is evaluating two additional areas of major unmet clinical needs for future development or partnering.
Cardiovascular Disease: Cardiovascular disease is the single largest killer of Americans, claiming the lives of over one million annually (American Heart Association). Preclinical studies have shown that Chrysalin® reduces restenosis, protects heart muscle from effects of acute myocardial infarction, and helps to restore vascular perfusion and function to the left ventricle of hearts with chronic myocardial ischemia.
Tissue Repair and Regenerative Medicine: In spite of medical advances, there are no successful treatments for many types of injury and diseases especially in an aging population. Use of stem cell therapies are being used to address these clincal problems. Clinical trials have shown potential efficacy of Chrysalin® in treating diabetic foot ulcers and distal radius fractures. These effects are mediated by activation and recruitment of endogenous progenitor cells located within tissues bypassing the need for stem cell therapy. By activating normal progenitor stem cells within tissues Chrysalin® may revolutionize the practice of regenerative medicine.